CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

The Mpox outbreak has renewed interest in Kenya from various foreign vaccine suppliers. One of the few WHO-approved Mpox ...

The most special thing about a vaccine is that it not only controls or reduces the disease, but taking it does not cause the ...

While the number of COVID-19 patients is on the rise, the Korea Centers for Disease Control and Prevention has signed a ...

The tide is turning in America’s COVID policy, with the recent announcement that the federal government will no longer recommend booster shots for most healthy Americans under the age of 65. This ...

Notably, Pfizer’s Comirnaty Covid vaccine is still approved or authorized for people 6 months of age and older without any restrictions based on risk factors for Covid — at least for now. But the FDA ...